Key Takeaways
- Steady 14% topline, margin mix shift: Revenue grew 14% YoY, in line with guidance, while gross margin expanded 200 bps to 79%. EBITDA margin, however, declined to 27% from 29% as elevated brand investments and a one-off forex loss weighed on operating profit. Excluding the forex loss, EBITDA margin was 29%, equal to last year.
- US Generics is the growth engine: The segment surged 36% YoY, fueled by full-quarter sales of five H2 FY25 launches and market share gains on limited-competition products. Management expects the current run rate to sustain for the rest of FY26.
- India outperforms, but cardiology lags: India business grew 16% YoY, outpacing IPM growth of 8% on stronger volumes and new launches. The cardiology division, however, lost share to competitive intensity, and a recovery is expected to take 3-4 quarters.
- Brand investments compress near-term EBITDA: A 42% YoY rise in other expenses, driven by MR additions, new therapy launches, and a Rs. 25 crore mark-to-market forex loss, pushed full-year EBITDA margin guidance to 27% (+/-1%). Expansion is promised for FY27.
- What to watch next quarter: Whether the cardiology division begins to close its growth gap with IPM, the pace of new US ANDA filings to refill the pipeline, and any inorganic move, with management actively pursuing branded generic acquisitions in India.
India Branded Formulations
- Broad-based outperformance: India revenue grew 16% YoY versus 8% IPM growth, driven by volume growth 73% higher than the market and new launch contribution 46% higher, as per IQVIA MAT June 2025. Price growth was also marginally ahead of IPM.
- New therapy build-out: Gynecology and nephrology divisions, launched less than a year ago, are taking shape. Management will review their performance only by year-end, with meaningful contribution expected in coming years.
- Field force expansion: 70 medical representatives were added in Q1, with another ~80 planned for the rest of FY26, bringing the total to ~150 for the year. This investment is a key driver of elevated other expenses.
- Cardiology soft spot: The division grew below IPM due to increasing competitive intensity and volume underperformance in certain brands, not pricing pressure. Corrective measures are underway, but management expects a 2-3 quarter lag before growth matches IPM.
Arvind Agrawal: "I think it is a small way of competition, which is increasing, but I think we already started working on it, and we should be able to certainly come back to our normal IPM growth. So, we will come back on that. It's just that it is a time lag, maybe in another 2, 3 quarters, you will start seeing the improvement."
US Generics
- Run rate visibility: The 36% YoY growth was driven by five products launched in H2 FY25 and one in Q1 FY26, plus market share gains as some competitors exited existing products. Management declined to speculate on competitor reasons, citing possible capacity or regulatory factors.
- Sustaining the base: Current quarterly revenue is expected to sustain for the remaining three quarters of FY26, supported by limited-competition products with stable visibility. No additional limited-competition products are expected this year.
- Pipeline replenishment: Two to three more launches are planned for FY26, and the company is confident of filing around 10 ANDAs during the year, plus or minus one or two. R&D spend dipped to 4% of revenue in Q1 only because no ANDAs were filed during the quarter; full-year R&D is expected at 5%.
- Capacity sufficient: Existing manufacturing plants are adequate for the US business, with no investment needed. A new liquid facility at Pithampur is for emerging markets, not the US.
Yogesh Agrawal: "We have some products which are limited competition products, and we believe that the visibility which we have, they should remain like that for the whole current year. We don't expect any addition in that limited competition products. So, we feel comfortable giving the guidance that the current run rate should continue for the rest of the 3 quarters."
Asia & Africa Branded Generics
- Asia growth below full-year pace: Asia branded generics grew 10% YoY, below the mid-teens full-year guidance. Management attributed the gap to quarter-to-quarter lumpiness from export shipment timing and inventory movements, and reiterated confidence in the full-year target. Ten new products were launched in Q1, primarily in chronic therapies.
- Africa flattish on a high base: Africa branded generics degrew 1% YoY, but this was against a 28% growth base in the prior year. On a two-year blended basis, growth exceeds 16-17%. Full-year FY26 is guided to mid- to high single-digit growth, with a bounce-back to double digits expected next year as the base effect normalizes.
- Africa Institution unpredictable: The institutional tender business degrew 8% YoY, and management maintained a cautious outlook due to dependence on procurement agencies, which makes the business inherently lumpy.
- Trade generics subdued: The small trade generic business was flattish to down 6% in Q1, with full-year expectation of around 10% growth.
Yogesh Agrawal: "If you take a blended 2-year growth, it will still be in excess of 16%, 17% growth. So, actually, there is no such correction which is required. We are doing just fine."
Margins & Cost Structure
- Gross margin tailwind: Gross margin improved 200 bps YoY to 79%, helped by a better product mix, favorable API prices, and a ~1% one-off benefit from lower provisioning for returns and expiries. Full-year gross margin is expected around 78% plus or minus 1%.
- EBITDA margin compressed: EBITDA margin declined to 27% from 29% YoY, driven by higher personnel costs from MR additions and selling expenses for new therapies and divisions added in H2 FY25. Excluding the Rs. 25 crore forex loss, EBITDA margin was 29%, equal to last year.
- Forex loss detail: The Rs. 25 crore mark-to-market loss arose from a sudden euro movement from 93 to 100 against the rupee within one month. Management characterized it as one-time and expects the euro not to go beyond current levels.
- Investment intensity to persist: Other expenses rose 42% YoY and are expected to stay elevated in the mid-teen range for FY26, reflecting continued investment in the branded generic business. Full-year EBITDA margin guidance is 27% (+/-1%), with expansion expected in FY27 as most expense increases are absorbed this year.
- Working capital at peak: Management believes working capital efficiency has reached its peak, with no further improvement expected from current levels.
Arvind Agrawal: "No, I think we have reached quite peak. From here, we don't expect any further achievement or efficiency in the working capital cycle."
Capital Allocation & Inorganic Strategy
- M&A actively pursued: The company is actively pursuing acquisitions, with a primary focus on India, followed by Asia and Africa. Targets are branded generic businesses with synergy potential, and there is no forced timeline. India targets are those that would have a synergy with the company.
- No resource constraint across geographies: Management stated that resources for each geography are independent, and there is no need to prioritize one over another. The board will decide on dividend payout and reserves for potential acquisitions during the year.
- CapEx on track: Rs. 72 crores was spent in Q1 against a full-year guidance of Rs. 300 crores. Normal maintenance CapEx is Rs. 150-200 crores, with the balance allocated to capacity expansion, including the new liquid facility at Pithampur for emerging markets.
Yogesh Agrawal: "There's no requirement of prioritization in one geography or other. There are all kind of resources that are independent on each of the geographies, and they perform independently. There is no constraint on the resources for each of the geographies."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US Generics revenue run rate | Current quarterly run rate to sustain | Remaining 3 quarters of FY26 |
| US Generics launches | 2 to 3 more launches | FY26 |
| US ANDA filings | Around 10 filings, plus/minus 1 or 2 | FY26 |
| India business growth | 20-25% higher than IPM growth rate | FY26 |
| India cardiology recovery | Match IPM growth | 2-3 quarters |
| Asia branded generics growth | Mid-teens growth | FY26 |
| Africa branded generics growth | Mid- to high single-digit growth | FY26 |
| Trade generics growth | Around 10% growth | FY26 |
| Gross margin | Around 78%, plus/minus 1% | FY26 |
| R&D spend | 5% of revenue | FY26 |
| EBITDA margin | 27%, plus/minus 1% | FY26 |
| EBITDA margin expansion | Expansion expected as expense increases are absorbed | FY27 |
| CapEx | Rs. 300 crores | FY26 |
| Income tax rate | Around 23% | FY26 |
| Emerging markets MR headcount | Add ~250 people (~10% increase to ~2,250) | FY26 |
| India MR additions | ~150 total (70 added in Q1, ~80 more) | FY26 |
| New therapy review (nephrology, gynecology) | Performance review | Year-end FY26 |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue from operations | ₹1,303 cr, +14% YoY |
| Gross margin | 79%, +200 bps YoY; includes ~1% one-off benefit from returns provisioning |
| EBITDA | ₹351 cr, +6% YoY |
| EBITDA margin | 27%, vs 29% YoY |
| EBITDA (excl. MTM forex loss) | ₹376 cr, +14% YoY; margin 29% |
| PAT | ₹255 cr, +4% YoY |
| PAT margin | 20%, vs 21% YoY |
| PAT (excl. MTM forex loss) | +12% YoY; margin 21% |
| India business revenue | ₹409 cr, +16% YoY |
| India branded growth vs IPM | 10% vs 8% IPM, as per IQVIA MAT June 2025 |
| US Generics revenue | ₹310 cr, +36% YoY |
| Asia branded revenue | ₹304 cr, +10% YoY |
| Africa branded revenue | ₹228 cr, -1% YoY; flat in local currency |
| Africa Institution revenue | ₹38 cr, -8% YoY |
| R&D spend | 4% of revenue; ₹56 cr vs ₹51 cr YoY |
| Other expenses | ₹373 cr, +42% YoY; includes ₹25 cr MTM forex loss |
| Cash flow from operations | ₹282 cr; cash conversion ratio 80% |
| Free cash flow | ₹209 cr; FCF to PAT conversion 82% |
| ROCE | 33% at end of June 2025 |
| RONW | 26% at end of June 2025 |
| CapEx | ₹72 cr in Q1; full-year guidance ₹300 cr |
| India MR additions | 70 added in Q1; ~150 expected for full year (total additions for the year) |
| Emerging markets MR additions | 40 added in Q1; ~250 expected for full year |